by MarketsandMarkets. 19-20th September 2019. Philadelphia USA.
August 14, 2019
“The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectviely than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.”
Visit stand #2 at this meeting to meet our team and discuss how we might be able to drive your immuno-oncology programmes.